249 related articles for article (PubMed ID: 24766298)
21. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
Boeckmans J; Natale A; Rombaut M; Buyl K; Rogiers V; De Kock J; Vanhaecke T; M Rodrigues R
Cells; 2019 Dec; 9(1):. PubMed ID: 31877771
[TBL] [Abstract][Full Text] [Related]
22. Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies.
Zhang CH; Zhou BG; Sheng JQ; Chen Y; Cao YQ; Chen C
Pharmacol Res; 2020 Sep; 159():104984. PubMed ID: 32502637
[TBL] [Abstract][Full Text] [Related]
23. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease.
Polyzos SA; Kountouras J; Zavos C; Tsiaousi E
Diabetes Obes Metab; 2010 May; 12(5):365-83. PubMed ID: 20415685
[TBL] [Abstract][Full Text] [Related]
24. Treatment options for nonalcoholic steatohepatitis - a safety evaluation.
Issa D; Wattacheril J; Sanyal AJ
Expert Opin Drug Saf; 2017 Aug; 16(8):903-913. PubMed ID: 28641031
[TBL] [Abstract][Full Text] [Related]
25. Roles of PPARs in NAFLD: potential therapeutic targets.
Tailleux A; Wouters K; Staels B
Biochim Biophys Acta; 2012 May; 1821(5):809-18. PubMed ID: 22056763
[TBL] [Abstract][Full Text] [Related]
26. Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism.
Rouabhia S; Milic N; Abenavoli L
Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):343-9. PubMed ID: 24580044
[TBL] [Abstract][Full Text] [Related]
27. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options.
Grander C; Grabherr F; Tilg H
Cardiovasc Res; 2023 Aug; 119(9):1787-1798. PubMed ID: 37364164
[TBL] [Abstract][Full Text] [Related]
28. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis.
Venetsanaki V; Karabouta Z; Polyzos SA
Eur J Pharmacol; 2019 Nov; 863():172661. PubMed ID: 31536725
[TBL] [Abstract][Full Text] [Related]
29. Emerging Therapies for Nonalcoholic Fatty Liver Disease.
Hameed B; Terrault N
Clin Liver Dis; 2016 May; 20(2):365-85. PubMed ID: 27063275
[TBL] [Abstract][Full Text] [Related]
30. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
[TBL] [Abstract][Full Text] [Related]
31. Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets.
Higuera-de la Tijera F; Servín-Caamaño AI
World J Hepatol; 2015 Jun; 7(10):1297-301. PubMed ID: 26052375
[TBL] [Abstract][Full Text] [Related]
32. Farnesoid X receptor modulators 2014-present: a patent review.
Sepe V; Distrutti E; Fiorucci S; Zampella A
Expert Opin Ther Pat; 2018 May; 28(5):351-364. PubMed ID: 29649907
[TBL] [Abstract][Full Text] [Related]
33. Regulation of energy metabolism by long-chain fatty acids.
Nakamura MT; Yudell BE; Loor JJ
Prog Lipid Res; 2014 Jan; 53():124-44. PubMed ID: 24362249
[TBL] [Abstract][Full Text] [Related]
34. Review article: new treatments in non-alcoholic fatty liver disease.
Townsend SA; Newsome PN
Aliment Pharmacol Ther; 2017 Sep; 46(5):494-507. PubMed ID: 28677333
[TBL] [Abstract][Full Text] [Related]
35. Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease.
Pan J; Zhou W; Xu R; Xing L; Ji G; Dang Y
Biomed Pharmacother; 2022 Jul; 151():113127. PubMed ID: 35598367
[TBL] [Abstract][Full Text] [Related]
36. Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD.
Vitulo M; Gnodi E; Rosini G; Meneveri R; Giovannoni R; Barisani D
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628929
[TBL] [Abstract][Full Text] [Related]
37. Anti-diabetic drugs and NASH: from current options to promising perspectives.
Smati S; Canivet CM; Boursier J; Cariou B
Expert Opin Investig Drugs; 2021 Aug; 30(8):813-825. PubMed ID: 34214406
[No Abstract] [Full Text] [Related]
38. Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease.
Sun DQ; Wu SJ; Liu WY; Lu QD; Zhu GQ; Shi KQ; Braddock M; Song D; Zheng MH
Expert Opin Ther Targets; 2016; 20(3):375-87. PubMed ID: 26419119
[TBL] [Abstract][Full Text] [Related]
39. The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease.
Yang Z; Danzeng A; Liu Q; Zeng C; Xu L; Mo J; Pingcuo C; Wang X; Wang C; Zhang B; Zhang B
Int J Biol Sci; 2024; 20(1):113-126. PubMed ID: 38164174
[TBL] [Abstract][Full Text] [Related]
40. Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment.
Che W; Zhao M; Li X; Li C; Cho WC; Yu S
Front Endocrinol (Lausanne); 2022; 13():1002916. PubMed ID: 36523601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
